

wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.

15.-17. (Canceled)

18. (Currently amended) The method according to claim 14 wherein the one or more cannabinoids compound of formula 1 is present in an extract of at least one cannabis plant.

19. (Previously presented) The method according to claim 14, wherein the compound or the composition is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.

20.-21. (Canceled)

22. (Currently amended) The method according to claim 14, wherein the cannabinoid is CBC R^3 is a straight chain alkyl group.

23. (Currently amended) The method according to claim 14, wherein the cannabinoid is CBC-V R^3 is C_5H_{11} .

24. (Currently amended) The method according to claim 14, wherein the cannabinoids are CBC and CBC-V R^3 is C_5H_{11} .

25. (Previously presented) The method according to claim 18, wherein the extract comprises substantially all the naturally occurring cannabinoids in said at least one cannabis plant.

26. (Previously presented) The method according to claim 18, wherein the extract is enriched for CBC and/or CBC-V ~~cannabinchrome~~.

27. (Previously presented) The method according to claim 14, wherein the compound is administered in an isolated and substantially pure form.
28. (Previously presented) The method according to claim 14, wherein the compound is administered together with one or more pharmaceutically acceptable diluents, excipients or carriers.